R
0.667
-0.07 (-9.13%)
| Penutupan Terdahulu | 0.734 |
| Buka | 0.680 |
| Jumlah Dagangan | 462,100 |
| Tarikh Pendapatan | 14 May 2026 |
| EPS Cair (TTM) | -0.250 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.57% |
| Nisbah Semasa (MRQ) | 0.130 |
| Aliran Tunai Operasi (OCF TTM) | -8.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.21 M |
| Pulangan Atas Aset (ROA TTM) | -8.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -53.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Lunai Bioworks Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.7 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.14 |
|
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 47.27% |
| % Dimiliki oleh Institusi | 12.85% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |